Calculating risk in glaucoma

Article

Using a risk calculator might impact ocular hypertension treatment options, concluded a study published in the December 2008 issue of the Journal of Ophthalmology.

Using a risk calculator might impact ocular hypertension treatment options, concluded a study published in the December 2008 issue of the Journal of Ophthalmology.

Michael V. Boland, MD, PhD of Johns Hopkins University, Baltimore, US and colleagues used the Ocular Hypertension Treatment Study to create two scenarios with equal risk of glaucoma development, only one of which included an estimate of glaucoma risk. The team then asked glaucoma specialists to review the scenarios and make treatment recommendations, and compared the differences in these recommendations based on whether glaucoma risk had previously been identified.

The researchers found that the presence of the glaucoma risk calculator increased the specialists' confidence and consistency in their own treatment recommendations. The physicians evaluated risk factors differently based on the presence or absence of the risk calculator.

Thus the researchers concluded that presence of a risk calculator altered treatment recommendations to the extent that specialists were more reassured about their recommendations when a risk calculator was available.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.